Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

398 ARTÍCULOS , VIENDO DEL 31 AL 45

Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease

Schaduangrat N, Prachayasittikul V, Choomwattana S, Wongchitrat P, Phopin K, Suwanjang W, Malik AA, Vincent B, Nantasenamat C.

Med Res Rev. 2019 Sep;39(5):1730-1778. doi: 10.1002/med.21563. Epub 2019 Jan 9.

Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

Madav Y, Wairkar S, Prabhakar B.

Brain Res Bull. 2019 Mar;146:171-184. doi: 10.1016/j.brainresbull.2019.01.004. Epub 2019 Jan 8.

Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Panza F, Lozupone M, Seripa D, Imbimbo BP.

Ann Neurol. 2019 Mar;85(3):303-315. doi: 10.1002/ana.25410. Epub 2019 Jan 28.

Procyanidins and Alzheimer's Disease

Zhao S, Zhang L, Yang C, Li Z, Rong S.

Mol Neurobiol. 2019 Aug;56(8):5556-5567. doi: 10.1007/s12035-019-1469-6. Epub 2019 Jan 16.

The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease

Sun J, Martin JM, Vanderpoel V, Sumbria RK.

Neuromolecular Med. 2019 Mar;21(1):12-24. doi: 10.1007/s12017-019-08524-y. Epub 2019 Jan 17.

A short perspective on the long road to effective treatments for Alzheimer's disease

Reynolds DS.

Br J Pharmacol. 2019 Sep;176(18):3636-3648. doi: 10.1111/bph.14581. Epub 2019 Mar 1.

Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule

Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I.

Biomolecules. 2019 Jan 21;9(1):34. doi: 10.3390/biom9010034.

Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease

Dubey SK, Ram MS, Krishna KV, Saha RN, Singhvi G, Agrawal M, Ajazuddin, Saraf S, Saraf S, Alexander A.

Cell Mol Neurobiol. 2019 Mar;39(2):181-209. doi: 10.1007/s10571-019-00653-z. Epub 2019 Jan 23.

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Kaeberlein M, Galvan V.

Sci Transl Med. 2019 Jan 23;11(476):eaar4289. doi: 10.1126/scitranslmed.aar4289.

Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer's Disease

Gulcan HO, Mavideniz A, Sahin MF, Orhan IE.

Curr Med Chem. 2019;26(18):3260-3278. doi: 10.2174/0929867326666190124123208.

Derivatives and Analogues of Resveratrol: Recent Advances in Structural Modification

Li QS, Li Y, Deora GS, Ruan BF.

Mini Rev Med Chem. 2019;19(10):809-825. doi: 10.2174/1389557519666190128093840.

Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease

Liyanage SI, Vilekar P, Weaver DF.

Can J Neurol Sci. 2019 Jan;46(1):23-34. doi: 10.1017/cjn.2018.353.

Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options

Cummings JL, Tong G, Ballard C.

J Alzheimers Dis. 2019;67(3):779-794. doi: 10.3233/JAD-180766.

The P2X7 receptor: a new therapeutic target in Alzheimer's disease

Illes P, Rubini P, Huang L, Tang Y.

Expert Opin Ther Targets. 2019 Mar;23(3):165-176. doi: 10.1080/14728222.2019.1575811.

Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease

Tiozzo Fasiolo L, Manniello MD, Bortolotti F, Buttini F, Rossi A, Sonvico F, Colombo P, Valsami G, Colombo G, Russo P.

J Drug Target. 2019 Nov;27(9):984-994. doi: 10.1080/1061186X.2019.1574300. Epub 2019 Feb 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias